Class / Patent application number | Description | Number of patent applications / Date published |
514160400 | Cardiac disease (i.e., heart disease) affecting | 76 |
20100249035 | PEPTIDES, COMPOSITIONS AND USES THEREOF - Described is an N-terminal hexapeptide fragment of maximakinin, QUB 698.8, which exhibits potent tissue selective actions on smooth muscle. It demonstrates a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle, causing potent relaxation of arterial smooth muscle, while causing less potent contraction of ileal smooth muscle. It may be used treatment of diseases of the cardiovascular system and in promotion of angiogenesis. | 09-30-2010 |
20100273713 | Diagnosis and Treatment of Congenital Heart Defects Using NELL1 - The present invention provides diagnostic methods for detecting congenital heart defects, or increased risk thereof, based on the Nell1 gene, RNA and protein. The methods include obtaining a biological sample and assessing the presence of a mutation in the Nell1 gene, RNA or protein. The presence of a mutation in the Nell1 gene, RNA or protein can be assessed by determining the levels of Nell1 gene, RNA or protein in the biological sample. The present invention further provides therapeutic methods for treating congenital heart defects based on the Nell1 gene, RNA and protein. | 10-28-2010 |
20100286051 | MEMORY AND LEARNING IMPAIRMENTS ASSOCIATED WITH DISRUPTION OF EPHRIN RECEPTOR A6 (EphA6) GENE - The present application is directed to a method of treating or preventing or ameliorating a neurological disorder associated with the disruption of a gene which encodes for an EphA6 polypeptide, the method comprising administering to a subject in need of such treatment whom may already have the disorder, or may be prone to have the disorder or may be in whom the disorder is to be prevented, a therapeutically effective amount of the therapeutic agent comprising a EphA6 polypeptide, or an agonist thereof, thereby effectively treating or preventing or ameliorating said disorder. | 11-11-2010 |
20110021433 | METHODS FOR TREATING OR PREVENTING HEART FAILURE - The invention provides methods for inhibiting cell death or inflammation in a mammal brought about by diseases or conditions such as heart failure, wherein the method comprises administering to a mammal in need thereof a Bcl protein in an amount sufficient to inhibit cell death and inflammation in the mammal. | 01-27-2011 |
20110046063 | READY-TO-USE BIVALIRUDIN COMPOSITIONS - Ready-to-use bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use bivalirudin compositions. The ready-to-use bivalirudin compositions comprise bivalirudin and one or more stabilizing agents. The one or more stabilizing agents may be buffering agents having a pKa of about 2.5 to about 6.5, pH-adjusting agents, polymers, preservatives, antioxidants, sugars or polyols, or a combination thereof. The ready-to-use bivalirudin compositions may also comprise [9-10]-cycloimido bivalirudin, [11-12]-cycloimido bivalirudin, or a combination thereof. The method of using the ready-to-use bivalirudin compositions comprises administering the ready-to-use compositions to a patient in need thereof. Further, the method of preparing the ready-to-use bivalirudin compositions comprises mixing bivalirudin with one or more stabilizing agents. | 02-24-2011 |
20110053853 | USE OF COPOLYMER 1 FOR TREATMENT OF MUSCULAR DYSTROPHY - The invention provides an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide and a Copolymer 1-related polypeptide, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising the active agent, for use in treating a muscular dystrophy disease or disorder. | 03-03-2011 |
20110065644 | COMPOSITIONS COMPRISING HUMAN PCSK9 AND APOLIPOPROTEIN B SIRNA AND METHODS OF USE - The present invention provides siRNA nucleic acid molecules that inhibit PCSK9 or apolipoprotein B expression. Methods of using the nucleic acid molecules are also provided. | 03-17-2011 |
20110071086 | COMPOSITIONS FOR TISSUE REPAIR/REGENERATION - The invention provides compositions and methods for cardiac repair and/or regeneration of tissues such as myocardium. | 03-24-2011 |
20110082085 | PEPTIDES DERIVED FROM THE C2 DOMAIN OF EPSILON PKC AND METHODS OF USE, THEREOF - Peptides derived from the C2 regions of εPKC and methods of use, thereof, are described. These peptides modulate the activity of εPKC in an animal model of acute ischemic heart disease. | 04-07-2011 |
20110092430 | METHOD AND COMPOUND FOR THE TREATMENT OF VALVULAR DISEASE - The present invention provides methods for preventing or treating a valvular stenosis or a valvular calcification in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a peptide/phospholipid complex, wherein the peptide of the complex is an Apolipoprotein A-1 mimetic peptide. In one embodiment the Apolipoprotein A-1 mimetic peptide has the sequence set forth in SEQ ID NO: 1. In another embodiment the phospholipid of the complex is egg sphingomyelin and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine. | 04-21-2011 |
20110105400 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTION - The present invention includes methods of treating acute myocardial infarction in a subject, comprising administering to the subject a therapeutically effective amount of a non-proteolytically activated thrombin receptor agonist. | 05-05-2011 |
20110112032 | Regulation of Brain Natriuretic Peptide and Catecholamines for the Treatment of Cardiovascular Diseases - The present invention describes methods for treating heart diseases by pharmacological manipulation of intrinsic cardiac adrenergic cells. The activation or inhibition of δ-opioid receptors or selective β2-adrenergic receptor agonist in these cells can help regulate catecholamine synthesis and release in these cells. Thus drugs directed towards these receptors can be used in the treatment of heart diseases including acute and chronic congestive heart failure, as well as acute and chronic coronary artery disease. The present invention also describes a method of treating acute decompensated congestive heart failure using δ-opioid receptor agonists or selective β2-adrenergic receptor agonists to stimulate endogenous production of brain natriuretic peptide. This invention also provides a novel strategy for protection against myocardial ischemia through the specific activation of δ-opioid receptors or selective β2-adrenergic receptor agonists exclusively expressed by intrinsic cardiac adrenergic cells in human heart. The activation of intrinsic cardiac adrenergic cells by δ-opioid receptor stimulation enhances endogenous catecholamine release, which subsequently stimulates myocardial alpha 1-adrenoreceptors achieving myocardial protection in patients suffering from myocardial ischemia due to coronary artery disease. | 05-12-2011 |
20110124567 | THERAPEUTIC COMPOUNDS AND METHODS - Therapeutic agents and methods useful to modulate the activity of V3. | 05-26-2011 |
20110124568 | USE OF HEAT-SHOCK PROTEIN 27 FOR CARDIOVASCULAR DISEASE PREVENTION AND TREATMENT - A method of reducing cholesterol in a subject is provided. The method may be used to decrease serum cholesterol and/or arterial wall cholesterol. The method comprises administering a therapeutically effective amount of heat shock protein 27 (HSP27), or a co-factor, variant or analogue thereof. The method may be used to treat, prevent or reverse cardiovascular disease (including atherosclerosis); to decrease atherosclerotic lesion formation or rupture; to decrease apoptosis within a plaque; to decrease macrophage accumulation; and/or to reverse the accumulation of atherosclerotic plaque mass in a subject. Kits and pharmaceutical compositions comprising HSP27 for preventing or treating of cardiovascular disease, such as atherosclerosis, are also provided. | 05-26-2011 |
20110130334 | Methods and Compositions for Treatment of Reperfusion Injury and other Cardiac Conditions - The present invention discloses methods to prevent and treat cardiovascular disorders, hi certain aspects the methods are drawn to releasing endogenous calcitonin-gene related peptide from intrinsic cardiac adrenergic cells within the heart. In further aspects, a combination of a β | 06-02-2011 |
20110130335 | THERAPEUTIC AGENT AND TEST AGENT FOR DISEASE WITH MYOCARDIAL NECROSIS - Disclosed are a medicament for treating or preventing diseases with myocardial necrosis, which contains, as an active ingredient, a periostin variant (ΔbΔe) polypeptide or a modified form thereof or a polynucleotide encoding the same; and a diagnostic agent for diseases with myocardial necrosis containing a DNA encoding a periostin variant (ΔbΔe) polypeptide or a partial fragment thereof or an antibody which specifically recognizes a periostin variant (ΔbΔe) polypeptide. | 06-02-2011 |
20110152194 | CHIMERIC NATRIURETIC POLYPEPTIDES AND METHODS FOR INHIBITING CARDIAC REMODELING - Materials and methods related to chimeric polypeptides containing the amino acid sequence of CNP and the C-terminal sequence of DNP. The polypeptides are natriuretic and diuretic, GFR enhancing, cardiac unloading, renin inhibiting and less hypotensive when compared to BNP. The polypeptides also inhibit cardiac fibroblast proliferation. | 06-23-2011 |
20110230412 | Neuregulin Peptides And Their Use - The present invention provides certain neuregulin peptides useful in, for example, methods and compositions comprising preventing, treating or delaying various diseases or disorders. | 09-22-2011 |
20110245179 | Composition for Prevention or Treatment of Heart Failure - Provided are a composition for preventing or treating heart failure and a method for screening an agent for treating heart failure. The present disclosure demonstrates for the first time that administration of PKCζ inhibitor provides inotropic effect by increasing myocardial contractility. Thus, the present disclosure will contribute greatly to the prevention or treatment of heart failure. Also, since the present disclosure is based on the change in calcium sensitivity in cardiac myocytes unlike the existing inotropic agents, it can enhance the myocardial contractility without increasing oxygen demand or the risk of arrhythmia. | 10-06-2011 |
20110251128 | THYMOSIN Beta4 PEPTIDES PROMOTE TISSUE REGENERATION - The present invention relates to thymosin β-4 peptides and analogs thereof that can promote tissues regeneration, particularly cardiac tissue. | 10-13-2011 |
20110269685 | PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE - The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair. | 11-03-2011 |
20110301089 | ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE - Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed. | 12-08-2011 |
20110306553 | METHODS AND USES INVOLVING HEME BINDING PROTEIN 1 - The present invention relates to a method of screening for a modulator of endothelial NO synthase (eNOS) expression, a method of diagnosing a cardiovascular disease in a subject, the use of HEBP-1 for the identification of a medicament for preventing and/or treating a disease involving eNOS dysfunction, particularly a cardiovascular disease, the use of HEBP-1 for the detection of a component of eNOS signal transduction, and the use of HEBP1 for the regulation of eNOS promoter activity. | 12-15-2011 |
20120035111 | Therapeutic Application of Adiponectin in Patients with Acute Myocardial Infarction - A therapeutic method for cardiac diseases such as angina, myocardial infarction, arrhythmia (ventricular tachycardia, ventricular fibrillation and atrial fibrillation) is provided. The method is characterized by intracoronary administration of adiponection to mammals. | 02-09-2012 |
20120040906 | PROTEIN TARGETS IN DISEASE - MicroRNAs have been shown to be critically involved in control of cell survival and cell death decisions. By identifying microRNAs implicated in Endoplasmic Reticulum stress-induced cardiomyocyte apoptosis, it is envisaged that protein targets involved in same can be identified through specifically selected microRNAs. The microRNAs targeted are miR-351, miR-322, miR-125, miR-424 and miR-7a. Furthermore, the potential application of these identified proteins in the treatment of cardiovascular disease, in particular congestive heart failure, is disclosed. | 02-16-2012 |
20120058946 | COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY - An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3′UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R) | 03-08-2012 |
20120058947 | PROPHYLACTIC AGENT FOR HEART FAILURE - The present invention provides an agent having a suppressive action against the thickening of the heart wall, a prophylactic agent for heart failure containing the above described agent, and functional foods expected to have a prophylactic effect for heart failure. The agent for suppressing heart wall thickening comprises Xaa Pro Pro as an active ingredient. | 03-08-2012 |
20120065139 | GQ PROTEIN COMPETITIVE INHIBITORY POLYPEPTIDES, PREPARATION METHODS AND USES THEREOF - Provided are a series of Gq protein competitive inhibitory polypeptides (GCIPs), polynucleotides encoding them, and preparation methods thereof. Also provided are pharmaceutical compositions comprising GCIP polypeptides and their uses in the manufacture of drugs for treating myocardial hypertrophy. | 03-15-2012 |
20120077750 | USE OF A GROWTH-STIMULATING PROTEIN - This invention relates to the inhibition of a newly discovered growth-stimulating protein in an individual. Further, the invention relates to a method for preventing or treating a cancer, or preventing or treating cancer growth, invasion or metastasis, or preventing or treating other hyperproliferative diseases in an individual, by down regulating the expression of said growth-stimulating protein or by inactivating said protein. Still further, the invention concerns a method for diagnosing cancer or other hyperproliferative diseases in an individual based on said growth-stimulating protein. | 03-29-2012 |
20120108514 | LONG ACTING ATRIAL NATRIURETIC PEPTIDE (LA-ANP) AND METHODS FOR USE THEREOF - Materials and Methods related to making and using natriuretic polypeptides having a mutation that results in an extended carboxy terminus. | 05-03-2012 |
20120122789 | Methods of Reducing Myocardial Injury Following Myocardial Infarction - The present invention discloses methods of reducing injury resulting from cardiovascular disease, such as myocardial infarction, and/or promoting myocardial repair. The methods include administering an ephrin and pharmaceutical compositions including ephrins to a subject. Kits useful for accomplishing the same are also provided. | 05-17-2012 |
20120208762 | Methods of Diagnosing Diastolic Dysfunction - Diagnostic methods relating to a cardiac ventricular dysfunction are provided. In some embodiments, the diagnostic method is a method of diagnosing diastolic dysfunction in the absence of systolic dysfunction in a subject. The method comprises assaying a sample obtained from the subject for evidence of activation of renin-angiontensin system (RAS), evidence of oxidative stress, a level of adiponectin, or a combination thereof, wherein, when there is a lack of evidence of RAS activation, a lack of evidence of oxidative stress, a reduction in the level of adiponectin, or a combination thereof, as compared to a control subject, the subject is diagnosed with diastolic dysfunction in the absence of systolic dysfunction. A method of diagnosing a type of cardiac ventricular dysfunction, a method of determining a therapeutic regimen for a subject suffering from a cardiac ventricular dysfunction and methods of treating diastolic dysfunction in the absence of systolic dysfunction are also provided. | 08-16-2012 |
20120270792 | UROCORTIN-III AND USES THEREOF - A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2α or β. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor. | 10-25-2012 |
20120270793 | METHODS OF TREATING A PATIENT RECEIVING A CARDIAC STENT IMPLANT - Methods of treating a patient receiving a cardiac stent implant including the steps of: (i) monitoring the circulating level of Tn I or CK-MB in the patient; and (ii) administering SERP-I to the patient in an amount sufficient to prevent the circulating level of Tn I or CK-MB from exceeding a specified threshold for the first 24 hours following implantation are disclosed. A specified value of SERP-I is sufficient for preventing circulating level of Tn I or CK-MB from exceeding a specified threshold during the first 24 hours following implantation. The dosing regime of SERP-I to the patient starting within 24 hours of post-implantation is also disclosed. | 10-25-2012 |
20120309684 | CONJUGATES FOR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS - A construct suitable for delivery of a biologically active compound into cells, comprising:
| 12-06-2012 |
20120329718 | COMPOSITIONS AND METHODS FOR TREATING ATRIAL FIBRILLATION - The present invention provides compositions and methods for treating heart conditions. In particular, the present invention provides compositions and methods that block G protein coupled receptor mediated signaling for treating atrial fibrillation. | 12-27-2012 |
20130005658 | MICRO-RNA REGULATION IN ISCHEMIA AND ISCHEMIA-REPERFUSION INJURY - The present invention relates to the identification of miRNAs that are involved in cardiac remodeling following ischemia and ischemia reperfusion injury. A subset of these miRNAs are regulated in the short term following an ischemic event indicating that these miRNAs play an important role in the induction of subsequent pathological events. Modulation of these identified miRNAs as a treatment or prevention for myocardial ischemia and ischemia reperfusion injury is described. | 01-03-2013 |
20130059786 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIAC AND VASCULAR DISEASE - The invention provides methods for the treatment of coronary heart disease, peripheral vascular disease, stroke, and ischemia featuring agents that interfere with the expression or activity of Cthrc1. The invention also provides the use of Cthrc1 peptide as a therapeutic agent for the treatment of acute or chronic cardiac deficiencies. The invention further provides detection and monitoring of Cthrc1 peptide in blood or serum to assess or monitor cardiac function. | 03-07-2013 |
20130116184 | RFamide-Related Peptides and Methods Thereof - Provided herein methods and compositions directed to RFRP-1 polypeptides for modulating cardiac contractile function, for preventing and/or treating cardiac disorders. | 05-09-2013 |
20130116185 | PHOSPHATIDYLINOSITOL 3-KINASES ACTIVITY REGULATOR INCLUDING THE FIFTH ZINC FINGER DOMAIN OF FOG2 - The present invention relates to a phosphatidylinositol 3-kinases activity regulator which include the fifth zinc finger domain of FOG2 and which, more specifically, can induce cancer cells to die due to the inclusion of the fifth zinc finger domain of FOG2. Since the death of cancer cells is induced by suppressing the transfer of PI3K signals, the fifth zinc finger domain of FOG2 according to the present invention can be suitably use as a composition for the prevention and treatment of PI3K-related diseases. | 05-09-2013 |
20130190244 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE - The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject. | 07-25-2013 |
20130196922 | BNIP3 ISOFORMS AND METHODS OF USE - The present invention provides isolated splice variants of Bnip3 and isolated polynucleotides encoding the splice variants. Also provided are isolated polypeptides present at the carboxy-terminus of Bnip3 splice variants, and antibody that specifically binds Bnip3 splice variants and/or the carboxy-terminus of Bnip3 splice variants. The present invention further provides methods of altering cellular apoptosis, cellular necrosis, cellular autophagy, or the combination thereof. For instance, the methods may include changing the amount of a Bnip3 splice variant or a carboxy-terminal region of a Bnip3 splice variant in a cell. Also provided herein are methods for determining whether death of cells in a tissue can be altered, methods for evaluating treatment options for a subject, and methods for identifying a compound that alters the amount or activity of a Bnip3 splice variant in a cell. | 08-01-2013 |
20130210734 | METHOD OF PREVENTING PROGRESSION OF HYPERTENSION-INDUCED HEART FAILURE WITH PKC PEPTIDES - Methods are described for slowing or inhibiting the progression of heart failure in a mammalian subject suffering from chronic hypertension. The methods involve administering an εPKC, β | 08-15-2013 |
20130237483 | Lipoyl Compounds And Their Use for Treating Ischemic Injury - The present invention relates, in various embodiments, to a compound represented by Structural Formula (I), pharmaceutically acceptable salts or prodrugs thereof, and compositions comprising said compounds, or pharmaceutically acceptable salts or prodrugs thereof. Methods of using compounds of Structural Formulas (I) and (la) or compositions comprising compounds of Structural Formulas (I) and (la), or pharmaceutically acceptable salts or prodrugs thereof, to treat ischemia or ischemia-reperfusion injury are also disclosed. | 09-12-2013 |
20130267469 | IPA AS A THERAPEUTIC AGENT, AS A PROTECTIVE AGENT, AND AS A BIOMARKER OF DISEASE RISK - Indole-3-propionic acid as a marker and for treatment for Huntington Disease. | 10-10-2013 |
20130288971 | SHORT PEPTIDES FOR ENHANCING MUSCLE FUNCTION - The present invention relates to shortened peptides comprising a muscle function enhancing amino acid sequence which is derived from the S100 calcium binding protein family. Furthermore, the present invention provides said peptides for medical use, in particular, for treating or preventing disorders associated with muscular malfunction, such as skeletal muscle or cardiac muscle disorders. The present invention also provides a pharmaceutical compositions comprising said peptides and a method for treating or preventing disorders associated with muscular malfunction using said peptides or said pharmaceutical compositions. | 10-31-2013 |
20130303457 | CELL-PROTECTIVE PEPTIDES AND USES THEREOF - A peptide comprising the amino acid sequence, X | 11-14-2013 |
20130310320 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES - Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses. | 11-21-2013 |
20130310321 | DIAGNOSTIC AGENT FOR ISCHEMIC HEART DISEASE RISK GROUP - The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor. | 11-21-2013 |
20130324472 | THERAPEUTIC METHOD FOR TREATING CONGESTIVE HEART FAILURE - The present invention relates to a method of treating congestive heart failure (CHF) in a subject comprising administering a peptide derived from atrial natriuretic peptide (ANP) prohormone (eg vessel dilator; VSDL) or a mimetic thereof. In a particular application, the invention provides a method of treating the particular indication known as acute decompensated congestive heart failure (ADCHF). Devices for intravenous or subcutaneous infusion for use in the method of the invention are also disclosed. | 12-05-2013 |
20140024594 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIAC ISCHEMIC INJURY - Disclosed herein are compositions and methods for the treatment and/or prevention of pathological conditions associated with ischemia/reperfusion injury and/or hypoxic injury of myocardial cell or tissue. | 01-23-2014 |
20140024595 | PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE - The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair. | 01-23-2014 |
20140045758 | Methods for Treating and Preventing Cardiac Dysfunction in Septic Shock - Cardiac dysfunction during sepsis is due, at least in part, to cardiac energy deficiency. It has been discovered that lipopolysaccharide (LPS)-mediated cardiac dysfunction is prevented or treated by treatments that improve FA oxidation (FAO), despite the persistence of inflammation. The present invention relates to methods for increasing or maintaining cardiac function in a subject, by administering to the subject a therapeutically effective amount of an agent that increases fatty acid oxidation in the heart. | 02-13-2014 |
20140100167 | ASSESSMENT OF CARDIAC HEALTH AND THROMBOTIC RISK IN A PATIENT - The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis. | 04-10-2014 |
20140179610 | TREATMENT OF TYPE 2 DIABETES, METABOLIC SYNDROME, MYOCARDIAL INJURY AND NEURODEGENERATION WITH HUMANIN AND ANALOGS THEREOF - Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity. | 06-26-2014 |
20140194362 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof - The present invention provides a novel class of macrocyclic compounds, which are useful as cysteine protease inhibitors. Also provided are novel intermediates and methods of preparing the compounds. The invention also provides pharmaceutical compositions comprising the compounds. The compounds and compositions are useful in methods of treating or preventing one or more diseases associated with cysteine protease activity, particularly those associated with calpain activity. | 07-10-2014 |
20140274904 | INHIBITORS OF MITOCHONDRIAL FISSION AND METHODS OF USE THEREOF - The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on Drp1 GTPase activity, binding of Drp1 to Fis1, reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture. | 09-18-2014 |
20140329755 | COMBINATION THERAPY FOR THE TREATMENT OF ARRHYTHMIAS OR HEART FAILURE - The present invention relates to method of treating arrhythmias or heart failure comprising co-administration of a late I | 11-06-2014 |
20150031622 | RHOGEF12 IS A THERAPEUTIC TARGET FOR THE TREATMENT OF HEART FAILURE - The present invention relates to an inhibitor of the Rho guanine nucleotide exchange factor 12 (RhoGEF12) or an inhibitor of an activator of RhoGEF12 for use in the prevention and/or treatment of heart failure associated with cardiac hypertrophy and/or cardiac fibrosis and diseases associated therewith. Further, it relates also a method of treatment and methods for identifying inhibitors of Rho guanine nucleotide exchange factor 12 (RhoGEF12) or inhibitors of an activator of RhoGEF12. | 01-29-2015 |
20150080311 | COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY - An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3′UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R) | 03-19-2015 |
20150111830 | Methods and Compositions for Activation of Sirtuins with Annexin A1 Peptides - The present invention provides a method of treating, ameliorating or inhibiting sirtuin-associated disorders and/or conditions in a subject in need thereof, by administering to the subject an effective amount of an ANXA1 peptide. | 04-23-2015 |
20150119333 | METHODS OF INHIBITING ADVERSE CARDIAC EVENTS AND TREATING ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE USING GALECTIN-3 BINDING PROTEIN (GAL-3BP, BTBD17B, MAC-2 BINDING PROTEIN) - The invention provides Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide sequences and compositions that include Gal-3BP polypeptide sequences, and methods of using Gal-3BP polypeptide sequences, including modified forms and wild type (native) forms of Gal-3BP polypeptide, such as in treatment, diagnostic, detection and prognostic methods. | 04-30-2015 |
20150307847 | CARDIAC REPAIR BY REPROGRAMMING OF CARDIAC FIBROBLASTS INTO CARDIOMYOCYTES - The present invention involves the use of transcription factors including Tbx5, Mef2C, Hand2, myocardin and Gata4 to reprogram cardiac fibroblasts into cardiomyocytes, both in vitro and in vivo. Such methods find particular use in the treatment of patients post-myocardial infarction to prevent or limit scarring and to promote myocardial repair. | 10-29-2015 |
20150344888 | USP30 INHIBITORS AND METHODS OF USE - Inhibitors of USP30 and methods of using inhibitors of USP30 are provided. In some embodiments, methods of treating conditions involving mitochondrial defects are provided. | 12-03-2015 |
20150368296 | Method for preventing or treating heart diseases by using a composition containing an isolated peptide - This present invention discloses an isolated peptide which amino acid sequence is SEQ ID NO.:1. The isolated peptide can inhibit the expressions of signal transduction proteins related to the heart hypertrophy pathway, apoptosis of myocardial cells related proteins, and cardiac fibrosis related proteins to have effects of preventing such as apoptosis of myocardial cells, cardiac fibrosis, heart hypertrophy, cardiac inflammation or other heart diseases. Therefore, the peptide disclosed in this present invention can be an active ingredient of pharmaceutical composition to have effects for preventing or treating cardiovascular diseases. | 12-24-2015 |
20150368297 | Novel Peptide Compound for Inhibiting Restenosis and Promoting Re-Endothelialization and Method for Preparing the Same - Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent. | 12-24-2015 |
20160000822 | POLOXAMER THERAPY FOR HEART FAILURE - Provided methods of administering poloxamer 188 for treating heart failure by only a single short relatively high dose infusion, or by regimen that includes the single infusion followed by additional infusions at intervals of 1-4 weeks. | 01-07-2016 |
20160016998 | HIGH-AFFINITY MATRIPTASE INHIBITORS - The present invention relates to novel matriptase inhibitors. | 01-21-2016 |
20160033481 | RE-TRAFFICKING OF HERG REVERSES LONG QT SYNDROME 2 PHENOTYPE IN HUMAN IPS-DERIVED CARDIOMYOCYTES - The present invention relates to generating hiPSC-derived cardiomyocytes and embryoid bodies that recapitulate the disease phenotype of Long QT Syndrome and their use in developing pharmacological treatments thereof. The present invention also includes the use of a compound which inhibits the ubiquitin-proteasome pathway for the preparation of a medicament for the prophylaxis or treatment of a disease associated with prolonged ventricular repolarization (cardiac arrhythmia) caused by one or more mutations in the amino acid sequence of the hERG potassium channel. | 02-04-2016 |
20160038568 | TREATMENT OF HEART DISEASE BY INHIBITION OF THE ACTION OF RIBOSOMAL S6 KINASE 3 (RSK3) - The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAPβ, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAPβ binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3. | 02-11-2016 |
20160068571 | THERAPEUTIC AGENT FOR CARDIAC TAMPONADE | 03-10-2016 |
20160120931 | METHODS AND COMPOSITIONS FOR REGULATING SRCA2A EXPRESSION LEVELS IN MYOCARDIAL INFARCTION - The disclosure provides methods and compositions for increasing SERCA2a expression levels in a mammalian subject in need thereof. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide to subjects in need thereof. In some embodiments, the aromatic-cationic peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof such as acetate or trifluoroacetate salt. In some embodiments, the subject has suffered a myocardial infarction. | 05-05-2016 |
20160120933 | INHIBITORS OF MITOCHONDRIAL FISSION AND METHODS OF USE THEREOF - The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on Drp1 GTPase activity, binding of Drp1 to Fis1, reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture. | 05-05-2016 |
20160136229 | MATERIALS FOR POSITIVE CATHEPSIN B MODULATION AND METHODS OF USE FOR TREATING MILD COGNITIVE IMPAIRMENT (MCI), EARLY DEMENTIA, A-SYNUCLEINOPATHY, TRAUMATIC BRAIN INJURY, CARDIOMYOPATHY, EYE DISEASE AND SKIN DAMAGE - The present invention provides methods for treating a subject afflicted with i) Mild Cognitive Impairment (MCI), ii) early dementia, iii) early α-synucleinopathy, iv) traumatic brain injury, v) cardiomyopathy, vi) eye disease, or vii) skin damage, comprising administering to the subject at least one compound that increases the level of active cathepsin B in cells of the subject, or a pharmaceutically acceptable salt or ester thereof, in an amount that is effective to treat the subject. The present invention also provides compositions for treating a subject afflicted with i) Mild Cognitive Impairment (MCI), ii) early dementia, iii) early α-synucleinopathy, iv) traumatic brain injury, v) cardiomyopathy, vi) eye disease, or vii) skin damage. | 05-19-2016 |
20160194708 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | 07-07-2016 |
20190142899 | TREATMENT OF ISCHEMIA REPERFUSION INJURY USING ALPHA-2 MACROGLOBULIN | 05-16-2019 |